Hepatitis C

Diagnosis and treatment

Jeff T Wilkins, Jennifer K. Malcolm, Dimple Raina, Robert R. Schade

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk populations, and confirmatory testing includes quantification of virus by polymerase chain reaction. The U.S. Preventive Services Task Force recommends against routine screening for hepatitis C virus infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening in adults at high risk of infection. Current therapy for chronic hepatitis C virus includes pegylated interferon and ribavirin. Therapy is based on factors that predict sustained virologic response, and the goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis. In the future, multidrug regimens in combination with current therapies may be developed. Patients with chronic hepatitis C virus infection should be advised to abstain from alcohol use. Currently, there is no vaccine available to prevent hepatitis C virus infection; however, persons infected with hepatitis C virus should be vaccinated for hepatitis A and B. The American Association for the Study of Liver Diseases recommends ultrasound surveillance for hepatocellular carcinoma in persons with chronic hepatitis C virus infection and cirrhosis.

Original languageEnglish (US)
Pages (from-to)1351-1357
Number of pages7
JournalAmerican Family Physician
Volume81
Issue number11
StatePublished - Jun 1 2010

Fingerprint

Hepatitis C
Hepacivirus
Virus Diseases
Fibrosis
Chronic Hepatitis C
Infection
Hepatocellular Carcinoma
Therapeutics
Hepatitis A
Ribavirin
Advisory Committees
Hepatitis B
Interferons
Vaccines
Alcohols
Viruses
Morbidity
Polymerase Chain Reaction
Mortality
Population

ASJC Scopus subject areas

  • Family Practice

Cite this

Wilkins, J. T., Malcolm, J. K., Raina, D., & Schade, R. R. (2010). Hepatitis C: Diagnosis and treatment. American Family Physician, 81(11), 1351-1357.

Hepatitis C : Diagnosis and treatment. / Wilkins, Jeff T; Malcolm, Jennifer K.; Raina, Dimple; Schade, Robert R.

In: American Family Physician, Vol. 81, No. 11, 01.06.2010, p. 1351-1357.

Research output: Contribution to journalArticle

Wilkins, JT, Malcolm, JK, Raina, D & Schade, RR 2010, 'Hepatitis C: Diagnosis and treatment', American Family Physician, vol. 81, no. 11, pp. 1351-1357.
Wilkins JT, Malcolm JK, Raina D, Schade RR. Hepatitis C: Diagnosis and treatment. American Family Physician. 2010 Jun 1;81(11):1351-1357.
Wilkins, Jeff T ; Malcolm, Jennifer K. ; Raina, Dimple ; Schade, Robert R. / Hepatitis C : Diagnosis and treatment. In: American Family Physician. 2010 ; Vol. 81, No. 11. pp. 1351-1357.
@article{4c04921131654623ac98af917daa8e04,
title = "Hepatitis C: Diagnosis and treatment",
abstract = "Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk populations, and confirmatory testing includes quantification of virus by polymerase chain reaction. The U.S. Preventive Services Task Force recommends against routine screening for hepatitis C virus infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening in adults at high risk of infection. Current therapy for chronic hepatitis C virus includes pegylated interferon and ribavirin. Therapy is based on factors that predict sustained virologic response, and the goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis. In the future, multidrug regimens in combination with current therapies may be developed. Patients with chronic hepatitis C virus infection should be advised to abstain from alcohol use. Currently, there is no vaccine available to prevent hepatitis C virus infection; however, persons infected with hepatitis C virus should be vaccinated for hepatitis A and B. The American Association for the Study of Liver Diseases recommends ultrasound surveillance for hepatocellular carcinoma in persons with chronic hepatitis C virus infection and cirrhosis.",
author = "Wilkins, {Jeff T} and Malcolm, {Jennifer K.} and Dimple Raina and Schade, {Robert R.}",
year = "2010",
month = "6",
day = "1",
language = "English (US)",
volume = "81",
pages = "1351--1357",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "11",

}

TY - JOUR

T1 - Hepatitis C

T2 - Diagnosis and treatment

AU - Wilkins, Jeff T

AU - Malcolm, Jennifer K.

AU - Raina, Dimple

AU - Schade, Robert R.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk populations, and confirmatory testing includes quantification of virus by polymerase chain reaction. The U.S. Preventive Services Task Force recommends against routine screening for hepatitis C virus infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening in adults at high risk of infection. Current therapy for chronic hepatitis C virus includes pegylated interferon and ribavirin. Therapy is based on factors that predict sustained virologic response, and the goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis. In the future, multidrug regimens in combination with current therapies may be developed. Patients with chronic hepatitis C virus infection should be advised to abstain from alcohol use. Currently, there is no vaccine available to prevent hepatitis C virus infection; however, persons infected with hepatitis C virus should be vaccinated for hepatitis A and B. The American Association for the Study of Liver Diseases recommends ultrasound surveillance for hepatocellular carcinoma in persons with chronic hepatitis C virus infection and cirrhosis.

AB - Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk populations, and confirmatory testing includes quantification of virus by polymerase chain reaction. The U.S. Preventive Services Task Force recommends against routine screening for hepatitis C virus infection in asymptomatic adults who are not at increased risk of infection (general population). It found insufficient evidence to recommend for or against routine screening in adults at high risk of infection. Current therapy for chronic hepatitis C virus includes pegylated interferon and ribavirin. Therapy is based on factors that predict sustained virologic response, and the goal of therapy is to slow or halt progression of fibrosis and prevent the development of cirrhosis. In the future, multidrug regimens in combination with current therapies may be developed. Patients with chronic hepatitis C virus infection should be advised to abstain from alcohol use. Currently, there is no vaccine available to prevent hepatitis C virus infection; however, persons infected with hepatitis C virus should be vaccinated for hepatitis A and B. The American Association for the Study of Liver Diseases recommends ultrasound surveillance for hepatocellular carcinoma in persons with chronic hepatitis C virus infection and cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=77953704766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953704766&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 1351

EP - 1357

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 11

ER -